Newsletter | March 5, 2024

03.05.24 -- Finding New Treatments In Old Therapies

SPONSOR

Webinar: PBPK Modeling For Identifying And Mitigating Absorption Risks In Early Drug Development

Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies for early drug candidates and guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects. Click here to learn more.

FEATURED EDITORIAL

Finding New Treatments In Old Therapies

By Robert L. Quigley, MD, D.Phil.

Discover the types of repurposed drugs and tips for making them a reality with international healthcare consultant Robert L. Quigley, MD, D.Phil.

INDUSTRY INSIGHTS

Manufacturing Dry Powder Inhaled Formulations By Spray Drying

Q&A | Lonza

Kimberly Shepard, Ph.D., principal engineer in R&D, addresses the challenges associated with spray-drying late-stage lung cancer treatments, including proteins, peptides, and mAbs.

Investing In Capacity: API Commercial Manufacturing

Case Study | Cambrex

A pharmaceutical company sought a CMO with commercial manufacturing capabilities, expertise, and exemplary quality systems to find a cost-effective process to produce the API for a new drug.

Using Synthesis And Route Design Technology To Approach API Complexity

Article | By Dr. Ryan Littich, Lonza, and Dr. Juergen Swienty-Busch, Elsevier Information Systems

Leveraging computer-aided synthesis design technology and route scouting in the early stages of development can aid you in designing an efficient and cost-effective path to API manufacturing.

New Technologies To Improve Solubility Of Brick Dust Compounds

Q&A | Lonza

David Lyon, Ph.D., and Molly Adam answer attendee questions from a recent webinar about three enabling technologies designed to improve drug solubility in organic solvents for spray drying.

How Approved Drugs Have Evolved Since The '70s

Article | By Jamie Unwin, Chris Worrall, and Christian Jones, Nanoform

Drugs have become more lipophilic and complex in structure over time. Innovative strategies are needed to improve bioavailability of these new drugs.

Accelerating The Development And Scale-Up Of mRNA Vaccines

Article | Precision NanoSystems

Learn how downstream considerations can make the difference between success and failure on the path toward the commercialization of mRNA vaccines.